Pharmacokinetic profile and safety of 150 mg of maraviroc dosed with 800/100 mg of darunavir/ritonavir all once daily, with and without nucleoside analogues, in hiv-infected subjects

Journal of Antimicrobial Chemotherapy

Volumn 68, Issue 6, 2013, Pages 1348-1353

  Mora Peris, Borja ^a   Croucher, Adam ^b   Else, Laura J ^c   Vera, Jaime H ^a,b   Khoo, Saye ^c   Scullard, George ^b   Back, David ^c   Winston, Alan ^a,b  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b ST MARY S HOSPITAL   (United Kingdom)

^c UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

Antiretroviral therapy; HIV; HIV antiviral pharmacology; Nucleoside sparing

Indexed keywords

DARUNAVIR; EMTRICITABINE; MARAVIROC; RITONAVIR; TENOFOVIR;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; DRUG BLOOD LEVEL; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; MAXIMUM PLASMA CONCENTRATION; MEDICATION COMPLIANCE; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PROSPECTIVE STUDY; STEADY STATE;

ANTIRETROVIRAL THERAPY; HIV; HIV ANTIVIRAL PHARMACOLOGY; NUCLEOSIDE SPARING;

ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; AREA UNDER CURVE; CD4 LYMPHOCYTE COUNT; CYCLOHEXANES; DRUG THERAPY, COMBINATION; FEMALE; HALF-LIFE; HIV FUSION INHIBITORS; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RITONAVIR; RNA, VIRAL; SULFONAMIDES; TRIAZOLES;

EID: 84880510019     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkt006     Document Type: Article

References (37)

1. Antiretroviral Therapy Cohort Collaboration. Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies. Lancet 2008; 372: 293-9.
2. Egger M, May M, Chene G et al. Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. Lancet 2002; 360: 119-29.
3. Egger M, Hirschel B, Francioli P et al. Impact of new antiretroviral combination therapies in HIV infected patients in Switzerland: prospective multicentre study. Swiss HIV Cohort Study. BMJ 1997; 315: 1194-9.
4. Negredo E, Miro O, Rodriguez-Santiago B et al. Improvement of mitochondrial toxicity in patients receiving a nucleoside reversetranscriptase inhibitor-sparing strategy: results from the Multicenter Study with Nevirapine and Kaletra (MULTINEKA). Clin Infect Dis 2009; 49: 892-900.
5. Tebas P, Zhang J, Hafner R et al. Peripheral and visceral fat changes following a treatment switch to a non-thymidine analogue or a nucleoside-sparing regimen in HIV-infected subjects with peripheral lipoatrophy: results of ACTG A5110. J Antimicrob Chemother 2009; 63: 998-1005.
6. Williams I, Churchill D, Anderson J et al. British HIV Association guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy 2012. HIV Med 2012; 13 Suppl 2: 1-6.
7. Vandekerckhove L, Verhofstede C, Vogelaers D. Maraviroc: perspectives for use in antiretroviral-naive HIV-1-infected patients. J Antimicrob Chemother 2009; 63: 1087-96.
8. Gulick RM, Lalezari J, Goodrich J et al. Maraviroc for previously treated patients with R5 HIV-1 infection. N Engl J Med 2008; 359: 1429-41.
9. Abel S, Back DJ, Vourvahis M. Maraviroc: pharmacokinetics and drug interactions. Antivir Ther 2009; 14: 607-18.
10. Siccardi M, D'Avolio A, Nozza S et al. Maraviroc is a substrate for OATP1B1 in vitro and maraviroc plasma concentrations are influenced by SLCO1B1 521 T.C polymorphism. Pharmacogenet Genomics 2010; 20: 759-65.
11. Kumar GN, Rodrigues D, Buko AM et al. Cytochrome P450-mediated metabolism of the HIV-1 protease inhibitor ritonavir (ABT-538) in human liver microsomes. J Pharmacol Exp Ther 1996; 277: 423-31.
12. Abel S. An open, randomised, 2-way crossover study to investigate the effect of darunavir/ritonavir on the pharmacokinetics of maraviroc in healthy subjects. In: Abstracts of the Eighth International Workshop on Clinical Pharmacology of HIV Therapy, Budapest, April 2007. Abstract 55.
13. Hardy WD, Gulick RM, Mayer H et al. Two-year safety and virologic efficacy of maraviroc in treatment-experienced patients with CCR5-tropic HIV-1 infection: 96-week combined analysis of MOTIVATE 1 and 2. J Acquir Immune Defic Syndr 2010; 55: 558-64.
14. Else L, Watson V, Tjia J et al. Validation of a rapid and sensitive high-performance liquid chromatography-tandem mass spectrometry (HPLC-MS/MS) assay for the simultaneous determination of existing and new antiretroviral compounds. J Chromatogr B Analyt Technol Biomed Life Sci 2010; 878: 1455-65.
15. Taylor S, Dufty N, Watson J. MVC 300 mg once daily+DRV/RTV 800/ 100 mg once daily provides MVC trough concentrations comparable to trough concentrations in HIV-1 patients taking MVC 300 mg twice daily+TVD: implications for Phase 3 studies. In: Eighteenth Conference on Retroviruses and Opportunistic Infections, Boston, MA, 2011. Poster 636. Foundation for Retrovirology and Human Health, Alexandria, VA, USA.
16. Abel S, van der Ryst E, Rosario MC et al. Assessment of the pharmacokinetics, safety and tolerability of maraviroc, a novel CCR5 antagonist, in healthy volunteers. Br J Clin Pharmacol 2008; 65 Suppl 1: 5-18.
17. Weatherley B, Vourvahis M, McFadyen L. Modeling of maraviroc pharmacokinetics in the presence of atazanavir/ritonavir in healthy volunteers and HIV-1-infected patients. In: Abstracts of the Twelfth International Workshop on Clinical Pharmacology of HIV Therapy, Miami, FL, 2011. Abstract P_05.
18. Arribas JR, Clumeck N, Nelson M et al. The MONET trial: week 144 analysis of the efficacy of darunavir/ritonavir (DRV/r) monotherapy versus DRV/r plus two nucleoside reverse transcriptase inhibitors, for patients with viral load ,50 HIV-1 RNA copies/mL at baseline. HIV Med 2012; 13: 398-405.
19. Valantin MA, Lambert-Niclot S, Flandre P et al. Long-term efficacy of darunavir/ritonavir monotherapy in patients with HIV-1 viral suppression: week 96 results from the MONOI ANRS 136 study. J Antimicrob Chemother 2012; 67: 691-5.
20. EMEA. CELSENTRI Scientific Discussion. 2007. http://www.ema.europa. eu/docs/en_GB/document_library/EPAR_-_Scientific_Discussion/human/00 0811/WC500022194.pdf (14 January 2013, date last accessed).
21. Okoli C, Siccardi M, Thomas-William S et al. Once daily maraviroc 300 mg or 150 mg in combination with ritonavir-boosted darunavir 800/100 mg. J Antimicrob Chemother 2012; 67: 671-4.
22. Kakuda TN, Abel S, Davis J et al. Pharmacokinetic interactions of maraviroc with darunavir-ritonavir, etravirine, and etravirinedarunavir- ritonavir in healthy volunteers: results of two drug interaction trials. Antimicrob Agents Chemother 2011; 55: 2290-6.
23. Comparative Trial of Maraviroc versus Emtricitabine/Tenofovir both with Darunavir/Ritonavir in Antiretroviral-naive Patients Infected with CCR5 Tropic HIV 1 (MODERN). http://clinicaltrials.gov/ct2/show/study/ NCT01345630 (14 January 2013, date last accessed).
24. Garvey L, Latch N, Erlwein OW et al. The effects of a nucleoside-sparing antiretroviral regimen on the pharmacokinetics of ritonavir-boosted darunavir in HIV type-1-infected patients. Antivir Ther 2010; 15: 213-8.
25. Chittick GE, Zong J, Blum MR et al. Pharmacokinetics of tenofovir disoproxil fumarate and ritonavir-boosted saquinavir mesylate administered alone or in combination at steady state. Antimicrob Agents Chemother 2006; 50: 1304-10.
26. Taburet AM, Piketty C, Chazallon C et al. Interactions between atazanavir-ritonavir and tenofovir in heavily pretreated human immunodeficiency virus-infected patients. Antimicrob Agents Chemother 2004; 48: 2091-6.
27. Kaul S, Bassi K, Damle B. Pharmacokinetic evaluation of the combination of atazanavir, enteric coated didanosine and tenofovir disoproxil fumarate for a once daily antiretroviral regimen. In: Abstracts of the Forty-third Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, 2003. Abstract A-1616. American Society for Microbiology, Washington, DC, USA.
28. von Hentig N, Dauer B, Haberl A et al. Tenofovir comedication does not impair the steady-state pharmacokinetics of ritonavir-boosted atazanavir in HIV-1-infected adults. Eur J Clin Pharmacol 2007; 63: 935-40.
29. Parks DA, Jennings HC, Taylor CW et al. Pharmacokinetics of once-daily tenofovir, emtricitabine, ritonavir and fosamprenavir in HIV-infected subjects. AIDS 2007; 21: 1373-5.
30. Zong J, Chittick GE, Wang LH et al. Pharmacokinetic evaluation of emtricitabine in combination with other nucleoside antivirals in healthy volunteers. J Clin Pharmacol 2007; 47: 877-89.
31. Gilead. VIREAD Full Prescribing Information. 2012. http://www.gilead. com/pdf/viread_pi.pdf (14 January 2013, date last accessed).
32. Muirhead G. An investigation of the effects of tenofovir on the pharmacokinetics of the novel CCR5 inhibitor UK-427,857. In: Abstracts of the Seventh International Congress on Drug Therapy in HIV Infection, Glasgow, 2004. Abstract P282.
33. Croteau D, Best BM, Letendre S et al. Lower than expected maraviroc concentrations in cerebrospinal fluid exceed the wild-type CC chemokine receptor 5-tropic HIV-1 50% inhibitory concentration. AIDS 2012; 26: 890-3.
34. Riddler SA, Haubrich R, DiRienzo AG et al. Class-sparing regimens for initial treatment of HIV-1 infection. N Engl J Med 2008; 358: 2095-106.
35. Duvivier C, Ghosn J, Assoumou L et al. Initial therapy with nucleoside reverse transcriptase inhibitor-containing regimens is more effective than with regimens that spare them with no difference in short-term fat distribution: Hippocampe-ANRS 121 Trial. J Antimicrob Chemother 2008; 62: 797-808.
36. Taiwo B, Zheng L, Gallien S et al. Efficacy of a nucleoside-sparing regimen of darunavir/ritonavir plus raltegravir in treatment-naive HIV-1-infected patients (ACTG A5262). AIDS 2011; 25: 2113-22.
37. Gervasoni C, Cattaneo D. Pharmacokinetic concerns related to the AIDS Clinical Trial Group (ACTG) A5262 trial. AIDS 2012; 26: 398-400; author reply 397-8.